Pan-Pacific Lymphoma Conference

Fisher Presents on Diffuse Large B Cell Lymphoma Variant

fisher2Presenting at the 2014 Pan-Pacific Lymphoma Conference in Kohala, Hawaii, Fox Chase President and CEO Richard I. Fisher, MD, reviewed the biology, prognosis, and future therapies for double/triple hit, C-MYC alone diffuse large B cell lymphoma, a very aggressive variant that has poor response to standard therapy and poor overall survival. As more clinical research homes in on this disease, Fisher says, “the most provocative question is whether molecular abnormalities in these patients can be successfully targeted with new oral inhibitors.”